Non-Cochrane · intervention · PM41563595
Comparative outcomes of surpass streamline and evolve flow diverters in intracranial aneurysms: a comprehensive systematic review and meta-analysis of location, size, and morphology.
Rashidi Farhang, Habibi Mohammad Amin, Sabahi Mohammadmahdi, et al. · Neurosurgical review · 2026 · PubMed · doi:10.1007/s10143-025-04062-3
Findings
61 findings
| Population | ||||
|---|---|---|---|---|
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | None (single-arm pooled proportion) | Retreatment Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML | Proportion 0.03 [0.01, 0.04] GRADE not reported 10 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | None (single-arm pooled proportion) | All-cause mortality Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML | Proportion 0 [0, 0] GRADE not reported 22 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | None (single-arm pooled proportion) | Adequate occlusion (RROC I or II, OKM C or D, SMART 3 or 4) Last follow-up · Single-arm pooled event proportions; random-effects REML | Proportion 0.90 [0.87, 0.94] GRADE not reported 20 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | None (single-arm pooled proportion) | In-stent thrombosis Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML | Proportion 0.03 [0.01, 0.04] GRADE not reported 11 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | None (single-arm pooled proportion) | Complete occlusion 36 months · Single-arm pooled event proportions; random-effects REML | Proportion 0.83 [0.71, 0.95] GRADE not reported Studies not reported |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | None (single-arm pooled proportion) | Complete occlusion (Raymond-Roy I, OKM D, SMART 4) Last follow-up · Single-arm pooled event proportions; random-effects REML | Proportion 0.77 [0.71, 0.82] GRADE not reported 27 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | None (single-arm pooled proportion) | Adequate occlusion 6 months · Single-arm pooled event proportions; random-effects REML | Proportion 0.81 [0.71, 0.91] GRADE not reported 6 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | None (single-arm pooled proportion) | Adequate occlusion 36 months · Single-arm pooled event proportions; random-effects REML | Proportion 0.98 [0.93, 1.03] GRADE not reported 2 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | None (single-arm pooled proportion) | Parent artery or in-stent stenosis Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML | Proportion 0.06 [0.02, 0.10] GRADE not reported 14 studies |
| Patients with intracranial aneurysms treated with Surpass flow diverters | Surpass flow diverter (Streamline and Evolve combined) | None | Complete occlusion at 24 months 24 months | Pooled proportion 0.89 [0.74, 1.03] GRADE not reported 1 study |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | None (single-arm pooled proportion) | Complete occlusion 12 months · Single-arm pooled event proportions; random-effects REML | Proportion 0.75 [0.66, 0.84] GRADE not reported 7 studies |
| Patients with intracranial aneurysms treated with Surpass flow diverters | Surpass flow diverter (Streamline and Evolve combined) | None | Complete occlusion at 60 months 60 months | Pooled proportion 0.90 [0.84, 0.97] GRADE not reported Studies not reported |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | None (single-arm pooled proportion) | Adequate occlusion 12 months · Single-arm pooled event proportions; random-effects REML | Proportion 0.88 [0.80, 0.95] GRADE not reported 6 studies |
| Patients with intracranial aneurysms treated with Surpass flow diverters | Surpass flow diverter (Streamline and Evolve combined) | None | Adequate occlusion at 24 months 24 months | Pooled proportion 1.00 [1.00, 1.00] GRADE not reported 1 study |
| Patients with intracranial aneurysms treated with Surpass flow diverters | Surpass flow diverter (Streamline and Evolve combined) | None | Adequate occlusion at 60 months 60 months | Pooled proportion 0.98 [0.94, 1.01] GRADE not reported Studies not reported |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | None (single-arm pooled proportion) | Major complications (permanent morbidity, stroke, SAH, rupture, CCF) Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML | Proportion 0.05 [0.03, 0.07] GRADE not reported 21 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | None (single-arm pooled proportion) | Complete occlusion 6 months · Single-arm pooled event proportions; random-effects REML | Proportion 0.55 [0.43, 0.66] GRADE not reported 8 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Parent artery or in-stent stenosis Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML · Surpass Evolve | Proportion 0.08 [0.02, 0.15] GRADE not reported 8 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | All-cause mortality Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML · Surpass Evolve | Proportion 0 [0, 0] GRADE not reported 9 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Retreatment Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML · Surpass Streamline | Proportion 0.03 [0.02, 0.04] GRADE not reported 7 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | In-stent thrombosis Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML · Surpass Streamline | Proportion 0.04 [0.03, 0.06] GRADE not reported 4 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Complete occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Surpass Evolve | Proportion 0.69 [0.60, 0.79] GRADE not reported 10 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Adequate occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Surpass Streamline | Proportion 0.92 [0.87, 0.96] GRADE not reported 11 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Complete occlusion 12 months · Single-arm pooled event proportions; random-effects REML · Surpass Streamline | Proportion 0.75 [0.60, 0.89] GRADE not reported 4 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | In-stent thrombosis Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML · Surpass Evolve | Proportion 0 [0, 0] GRADE not reported 7 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Major complications Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML · Surpass Evolve | Proportion 0.02 [0.00, 0.04] GRADE not reported 9 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Complete occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Surpass Streamline | Proportion 0.81 [0.76, 0.87] GRADE not reported 17 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Complete occlusion 12 months · Single-arm pooled event proportions; random-effects REML · Surpass Evolve | Proportion 0.76 [0.63, 0.88] GRADE not reported 3 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Retreatment Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML · Surpass Evolve | Proportion 0.02 [-0.01, 0.04] GRADE not reported 3 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Adequate occlusion 6 months · Single-arm pooled event proportions; random-effects REML · Surpass Streamline | Proportion 0.84 [0.76, 0.93] GRADE not reported 2 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Parent artery or in-stent stenosis Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML · Surpass Streamline | Proportion 0.03 [0.01, 0.05] GRADE not reported 6 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Complete occlusion 6 months · Single-arm pooled event proportions; random-effects REML · Surpass Streamline | Proportion 0.64 [0.35, 0.93] GRADE not reported 2 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Adequate occlusion 12 months · Single-arm pooled event proportions; random-effects REML · Surpass Evolve | Proportion 0.90 [0.74, 1.06] GRADE not reported 2 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Adequate occlusion 6 months · Single-arm pooled event proportions; random-effects REML · Surpass Evolve | Proportion 0.79 [0.63, 0.95] GRADE not reported 4 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Major complications Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML · Surpass Streamline | Proportion 0.07 [0.04, 0.10] GRADE not reported 12 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | All-cause mortality Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML · Surpass Streamline; version in Supplementary File 3 (Mortality forest plot) | Proportion 0.01 [0.00, 0.01] GRADE not reported 13 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | All-cause mortality Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML · Surpass Streamline | Proportion 0.01 [0.00, 0.02] GRADE not reported 13 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Adequate occlusion 12 months · Single-arm pooled event proportions; random-effects REML · Surpass Streamline | Proportion 0.86 [0.77, 0.96] GRADE not reported 4 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Complete occlusion 6 months · Single-arm pooled event proportions; random-effects REML · Surpass Evolve | Proportion 0.52 [0.39, 0.65] GRADE not reported 6 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | Adequate occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Surpass Evolve | Proportion 0.88 [0.82, 0.95] GRADE not reported 9 studies |
| Patients with intracranial aneurysms | Surpass Evolve flow diverter | Surpass Streamline flow diverter (between-device difference tested) | All-cause mortality Follow-up (not specified) · Single-arm pooled event proportions; random-effects REML · Surpass Evolve; version in Supplementary File 3 (Mortality forest plot) | Proportion 0 [0, 0] GRADE not reported 9 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Anterior vs posterior circulation aneurysms (subgroup difference tested) | Adequate occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Posterior circulation | Proportion 1.00 [1.00, 1.00] GRADE not reported 8 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Anterior vs posterior circulation aneurysms (subgroup difference tested) | Complete occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Anterior circulation | Proportion 0.80 [0.73, 0.86] GRADE not reported Studies not reported |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Anterior vs posterior circulation aneurysms (subgroup difference tested) | Complete occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Posterior circulation; version in Supplementary File 3 (complete occlusion location forest plot) | Proportion 0.64 [0.43, 0.85] GRADE not reported 11 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Anterior vs posterior circulation aneurysms (subgroup difference tested) | Adequate occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Anterior circulation | Proportion 0.92 [0.87, 0.96] GRADE not reported 13 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Anterior vs posterior circulation aneurysms (subgroup difference tested) | Complete occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Posterior circulation | Proportion 0.64 [0.43, 0.85] GRADE not reported Studies not reported |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Anterior vs posterior circulation aneurysms (subgroup difference tested) | Complete occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Anterior circulation; version in Supplementary File 3 (complete occlusion location forest plot) | Proportion 0.79 [0.73, 0.85] GRADE not reported 15 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Small/medium (< 10 mm) vs large/giant (> 10 mm) aneurysms (subgroup difference tested) | Adequate occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Large/giant aneurysms | Proportion 1.00 [1.00, 1.00] GRADE not reported 10 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Small/medium (< 10 mm) vs large/giant (> 10 mm) aneurysms (subgroup difference tested) | Complete occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Large and giant aneurysms; version in Supplementary File 3 (complete occlusion size forest plot) | Proportion 0.78 [0.66, 0.89] GRADE not reported 12 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Small/medium (< 10 mm) vs large/giant (> 10 mm) aneurysms (subgroup difference tested) | Adequate occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Small/medium aneurysms | Proportion 0.88 [0.72, 1.03] GRADE not reported 5 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Small/medium (< 10 mm) vs large/giant (> 10 mm) aneurysms (subgroup difference tested) | Complete occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Large/giant aneurysms | Proportion 0.79 [0.68, 0.90] GRADE not reported Studies not reported |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Small/medium (< 10 mm) vs large/giant (> 10 mm) aneurysms (subgroup difference tested) | Complete occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Small aneurysms; version in Supplementary File 3 (complete occlusion size forest plot) | Proportion 0.70 [0.55, 0.85] GRADE not reported 6 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Small/medium (< 10 mm) vs large/giant (> 10 mm) aneurysms (subgroup difference tested) | Complete occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Small/medium aneurysms | Proportion 0.70 [0.55, 0.85] GRADE not reported Studies not reported |
| Patients with intracranial aneurysms treated with Surpass flow diverters | Surpass flow diverter by aneurysm morphology (blister, dissecting, fusiform, saccular) | Other aneurysm morphologies | Complete occlusion at last follow-up Last follow-up · Blister | Pooled proportion 1.00 [1.00, 1.00] GRADE not reported 4 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Blister, dissecting, fusiform and saccular aneurysms (subgroup difference tested) | Adequate occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Dissecting aneurysms | Proportion 1.00 [1.00, 1.00] GRADE not reported 4 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Blister, dissecting, fusiform and saccular aneurysms (subgroup difference tested) | Adequate occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Fusiform aneurysms | Proportion 0.75 [0.50, 1.01] GRADE not reported 9 studies |
| Patients with intracranial aneurysms treated with Surpass flow diverters | Surpass flow diverter by aneurysm morphology (blister, dissecting, fusiform, saccular) | Other aneurysm morphologies | Adequate occlusion at last follow-up Last follow-up · Blister | Pooled proportion 1.00 [1.00, 1.00] GRADE not reported 4 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Blister, dissecting, fusiform and saccular aneurysms (subgroup difference tested) | Complete occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Dissecting aneurysms | Proportion 0.65 [0.17, 1.14] GRADE not reported 4 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Blister, dissecting, fusiform and saccular aneurysms (subgroup difference tested) | Adequate occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Saccular aneurysms | Proportion 0.96 [0.93, 1.00] GRADE not reported 10 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Blister, dissecting, fusiform and saccular aneurysms (subgroup difference tested) | Complete occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Saccular aneurysms | Proportion 0.79 [0.68, 0.89] GRADE not reported 10 studies |
| Patients with intracranial aneurysms | Surpass flow diverter (Streamline or Evolve) | Blister, dissecting, fusiform and saccular aneurysms (subgroup difference tested) | Complete occlusion Last follow-up · Single-arm pooled event proportions; random-effects REML · Fusiform aneurysms | Proportion 0.55 [0.28, 0.81] GRADE not reported 10 studies |
Included primary studies 27
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Achey 2022 Use of Surpass Streamline Flow Diverter for the Endovascular Treatment of Craniocervical Aneurysms: A Single-Institution Experience. PMID:35276392 | 2022 | this review only | not stated | not extracted yet |
| Bibi 2024 Safety and efficacy of Surpass Evolve Flow diverter for intracranial aneurysms: A study of 116 patients. PMID:38146676 | 2024 | this review only | not stated | not extracted yet |
| Colby 2015 Flow diversion of large internal carotid artery aneurysms with the surpass device: impressions and technical nuance from the initial North… PMID:25987590 | 2016 | this review only | not stated | not extracted yet |
| De Vries 2013 New generation of Flow Diverter (surpass) for unruptured intracranial aneurysms: a prospective single-center study in 37 patients. PMID:23686973 | 2013 | this review only | not stated | not extracted yet |
| Dmytriw 2024 Comparative Efficacy of Flow Diverter Devices in the Treatment of Carotid Sidewall Intracranial Aneurysms: a Retrospective, Multicenter… PMID:39023541 | 2024 | this review only | not stated | not extracted yet |
| Feigen 2022 Pipeline Embolization Device and Pipeline Flex Versus Surpass Streamline Flow Diversion in Intracranial Aneurysms: A Retrospective… PMID:35151920 | 2022 | this review only | not stated | not extracted yet |
| Field 2023 Comparison of pipeline embolization device, flow re-direction endoluminal device and surpass flow diverters in the treatment of… PMID:37635329 | 2026 | this review only | not stated | not extracted yet |
| Gupta 2023 Surpass embolization of intracranial aneurysms: Perspective from a 2-year longitudinal follow-up study across high volume comprehensive… PMID:37464776 | 2025 | this review only | not stated | not extracted yet |
| Gupta 2024 Does Small Aneurysm Size (<10 mm) Predict Complete Occlusion After Flow Diversion? A Surpass Evolve Single-Center Study. PMID:38551334 | 2025 | this review only | not stated | not extracted yet |
| Han 2023 One-year clinical and radiologic outcomes of Surpass Evolve flow diverter for large unruptured intracranial aneurysms. PMID:38127302 | 2025 | this review only | not stated | not extracted yet |
| Jee 2022 Early clinical experience of using the Surpass Evolve flow diverter in the treatment of intracranial aneurysms. PMID:34453182 | 2022 | this review only | not stated | not extracted yet |
| Kan 2023 Treatment of large and giant posterior communicating artery aneurysms with the Surpass streamline flow diverter: results from the SCENT… PMID:35551072 | 2023 | this review only | not stated | not extracted yet |
| Mahajan 2018 Surpass Flow Diverter in the Treatment of Ruptured Intracranial Aneurysms-A Single-Center Experience. PMID:30213677 | 2018 | this review only | not stated | not extracted yet |
| Maus 2021 Initial Experience with Surpass Evolve Flow Diverter in the Treatment of Intracranial Aneurysms. PMID:33216156 | 2021 | this review only | not stated | not extracted yet |
| Meyers 2025 Five-year results of the SCENT trial with Surpass flow diverters to treat large or giant wide-neck aneurysms. PMID:40335285 | 2025 | this review only | not stated | not extracted yet |
| Ocal 2019 Placement of a Stent within a Flow Diverter Improves Aneurysm Occlusion Rates. PMID:31582390 | 2019 | this review only | not stated | not extracted yet |
| Orru 2020 First clinical experience with the new Surpass Evolve flow diverter: technical and clinical considerations. PMID:32051324 | 2020 | this review only | not stated | not extracted yet |
| Rautio 2022 Treatment of intracranial aneurysms using the new Surpass Evolve flow diverter: Safety outcomes and six-month imaging follow-up. PMID:33785389 | 2022 | this review only | not stated | not extracted yet |
| Sayin 2023 The Evaluation of Low-Profile Surpass EvolveTM Flow Diverter for Endovascular Treatment of Distal Cerebral Artery Aneurysms: A… PMID:37222015 | 2023 | this review only | not stated | not extracted yet |
| Siddiqui 2022 Triple therapy versus dual-antiplatelet therapy for dolichoectatic vertebrobasilar fusiform aneurysms treated with flow diverters. PMID:36190965 | 2023 | this review only | not stated | not extracted yet |
| Taschner 2016 Surpass Flow Diverter for Treatment of Posterior Circulation Aneurysms. PMID:28007769 | 2017 | this review only | not stated | not extracted yet |
| Ten Brinck 2021 Limitations of Flow Diverters in Posterior Communicating Artery Aneurysms. PMID:33803427 | 2021 | this review only | not stated | not extracted yet |
| Teranishi 2022 Preliminary Experience of the Surpass Streamline Flow Diverter for Large and Giant Unruptured Internal Carotid Artery Aneurysms. PMID:36070961 | 2022 | this review only | not stated | not extracted yet |
| Topcuoglu 2018 Intermediate catheter placement distal to the cerebral aneurysm during flow diversion embolization with the Surpass device. PMID:29695603 | 2018 | this review only | not stated | not extracted yet |
| Vivanco-Suarez 2023 Safety and efficacy of the surpass streamline for intracranial aneurysms (SESSIA): A multi-center US experience pooled analysis. PMID:35934939 | 2023 | this review only | not stated | not extracted yet |
| Vivanco-Suarez 2024 Safety and effectiveness assessment of the surpass evolve (SEASE): a post-market international multicenter study. PMID:38663997 | 2025 | this review only | not stated | not extracted yet |
| Wakhloo 2014 Surpass flow diverter in the treatment of intracranial aneurysms: a prospective multicenter study. PMID:25125666 | 2015 | this review only | not stated | not extracted yet |
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Patients diagnosed with intracranial aneurysms | 1,826 patients (76.7% female) with 2,006 intracranial aneurysms (1,743 anterior, 222 posterior; 28 blister, 20 dissecting, 116 fusiform, 1,597 saccular) (n=27 studies) |
| Intervention | Surpass flow diverters of any generation (Streamline, Evolve); studies of other stents or devices (FRED, PED) excluded | Surpass Streamline (17 studies, 1,225 aneurysms) and Surpass Evolve (10 studies, 781 aneurysms) |
| Comparison | No control group required; comparisons between Surpass Streamline and Evolve and between aneurysm subgroups | Single-arm studies; Streamline compared with Evolve |
| Outcomes | Complete and adequate occlusion (RROC, OKM, SMART), major complications, retreatment, parent artery or in-stent stenosis, in-stent thrombosis, mortality | Complete occlusion 77% and adequate occlusion 90% at last follow-up; major complications 5%; retreatment 3%; stenosis 6%; in-stent thrombosis 3%; mortality below 1% |
| Study designs | Original English studies with at least five patients; case reports and non-original studies excluded | 27 studies (two clinical trials, the rest mainly retrospective cohorts) published 2013 to 2024; NOS quality mostly high |
| Timing | Follow-up at 6, 12, 24, 36, 60 months and last follow-up | 6, 12, 24, 36 and 60 months and last follow-up |